Massive trial tests new river blindness drug against standard treatment
NCT ID NCT04311671
Summary
This large study compared the safety of a newer drug called moxidectin against the standard drug ivermectin for treating river blindness. It involved nearly 13,000 people aged 4 and older living in areas where the disease is common. Some participants also received an additional drug for a related parasitic infection to see if the combination was safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire
Abidjan, Côte d’Ivoire
-
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.